Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis

Chinese Journal of Pathology

Volumn 39, Issue 6, 2010, Pages 372-376

  Lin, Min ^a   Chen, Zhong Qing ^b   Bao, Yun ^b   Li, Qiong ^b   Du, Zun Guo ^b   Xu, Zu De ^b   Tang, Feng ^b  

^a FUDAN UNIVERSITY   (China)

^b NONE

Author keywords

Breast neoplasms; Carcinoma,ductal,breast; Disease free survival; Immunophenotyping

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BREAST TUMOR; CANCER STAGING; CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATIN-5; KERATIN-6; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR BURDEN;

EID: 77954685058     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2010.06.003     Document Type: Article

References (19)

1. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A, 2003, 100 (18): 10393-10398.
2. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295(21): 2492-2502.
3. Jacquemier J, Ginestier C, Rougemont J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res, 2005, 65(3): 767-779.
4. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights; international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol, 2005, 16(10):1569-1583.
5. Hammock L, Lewis M, Phillips C, et al. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol, 2003, 34(10):1043-1047.
6. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 2003, 100(14): 8418-8423.
7. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol, 2002, 161(6): 1991-1996.
8. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer; ready for clinical application? J Clin Oncol, 2005, 23(29): 7350-7360.
9. Ihiemelandu CU, Naab TJ, Mezghebe HM, et al. Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg, 2008, 247(3): 463-469.
10. Del Casar JM, Martin A, Garcia C, et al. Characterization of breast cancer subtypes by quantitative assessment of bioligical parameters: relationship with clinicopathological characteristics, biological features and prognosis. Eur J Obstet Gynecol Reprod Biol, 2008, 141(2): 147-152.
11. Rouzier R, Anderson K, Hess KR, et al. Basal and luminal types of breast cancer defined by gene expression patterns respond differently to neoadjuvant chemotherapy. Breast Cancer Res Treat, 2004, 88 Suppl 1: 24-25.
12. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemo-sensitivity of the basal-like breast cancer ( BBC ) phenotype. Breast Cancer Res Treat, 2004, 88 Suppl 1: 48-49.